# 2026-09269: FDA Guides Pharma on Battling Lung TB: Drugs That Actually Work

2026-09269, Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-11, effective 2026-05-11 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09269
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09269
- Title: Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 25580
- Published: 2026-05-11
- Effective: 2026-05-11
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Guides Pharma on Battling Lung TB: Drugs That Actually Work

## Summary

The FDA just released final guidance to help drug makers create new medicines to treat lung tuberculosis (TB). This update affects companies developing TB drugs by clarifying how to test and prove their treatments work safely and effectively. The guidance is official as of May 11, 2026, aiming to speed up better TB treatments without extra costs for the public.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Pulmonary Tuberculosis: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of new antibacterial drugs for the treatment of pulmonary tuberculosis (TB). This guidance finalizes the draft guidance of the same title issued on December 15, 2022.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09269 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/11/2026-09269/pulmonary-tuberculosis-developing-drugs-for-treatment-guidance-for-industry-availability)
- [2026-09269 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-11/pdf/2026-09269.pdf)

## Related
- [Previous: 2026-09268, Postapproval Pregnancy Safety Studies; Guidance for Industry; Availability](https://policyrisk.com/federal-register/2026-09268)
- [Next: 2026-09271, Endangered Species; File No. 29773](https://policyrisk.com/federal-register/2026-09271)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09269 (as of 2026-06-08).
